TY - JOUR T1 - Causes, Predictors, and Costs of Unplanned 30-Day Readmissions in Patients with Right Heart Failure JF - medRxiv DO - 10.1101/2021.06.28.21257859 SP - 2021.06.28.21257859 AU - Amod Amritphale AU - Jesan Zaman AU - Saad Awan AU - Nupur Amritphale AU - G. Mustafa Awan AU - Suvo Chatterjee AU - Bassam Omar AU - Gregg C. Fonarow Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/07/02/2021.06.28.21257859.abstract N2 - OBJECTIVES The aim of this study was to describe the frequency, causes, factors, and costs associated with right heart failure encounters.BACKGROUND Multiple studies have looked into heart failure readmissions but there is no study to our knowledge specifically analyzing patients with right heart failure.METHODS Patients with right heart failure diagnosis were identified using the 2017 Nationwide Readmission Database (NRD) and were evaluated for the rates, predictors, and costs of unplanned 30 days readmission. Weighted analysis was performed to obtain nationally representative data.RESULTS We identified 7142 patients with right heart failure of whom 21% had an unplanned readmission within 30 days of the index discharge. Patients with history of Coronary artery bypass grafting (p=0.033; OR 2.359; 95% CI 1.071 - 5.197), Chronic kidney disease (p<0.001; OR 1.607; 95% CI 1.402 - 1.843), atrial fibrillation (p=0.014; OR 1.417; 95% CI 1.072–1.873) had high odds of unplanned 30 day readmissions while obesity (p<0.001; OR 0.686; 95% CI 0.594 - 0.792) had negative odds of such readmissions.CONCLUSIONS Thirty-day unplanned readmissions remain a significant issue affecting over 1 in 5 patients with right heart failure. Early unplanned readmissions are associated with significant mortality and financial burden in these patients.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNo Clinical trials were conductedFunding StatementNo FundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study is based on publicly available deidentified database and was approved for exempt status by the IRB at University of South AlabamaAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is publicly available, we utilized the NRD DatabaseNRDNationwide Readmission DatabaseICDInternational Classification of DiseasesCMSCenters for Medicare & Medicaid ServicesRSRRRisk-Standardized Readmission RatesHRRPHospital Readmissions Reduction ProgramCADcoronary artery diseaseCVACerebro- Vascular accidentsCABGCoronary artery bypass graftingGIGastrointestinalCOPDChronic obstructive pulmonary diseaseCKDChronic kidney diseaseAKIAcute kidney injuryCCSRClinical Classification Software refinedIQRInter Quartile RangeAPR-DRGAll Patient Refined-Diagnosis Related GroupMACCEMajor Adverse Cardiovascular and Cerebrovascular EventsPADPeripheral artery disease ER -